Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Oct 2;8:3757–3768. doi: 10.2147/IJN.S51353

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Dong et al. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed.

PMC Copyright notice

Overall survival curves for different groups.

Notes: The mean and median survival time for Lipiodol® (Guerbet, Villepinte, France) (Group A, n = 16), nanoplex/Lipiodol (Group B, n = 25), nanoplex-p53/Lipiodol (Group C, n = 30), nanoplex-Rb/Lipiodol (Group D, n = 25), and nanoplex-(p53+Rb)/Lipiodol (Group E, n = 25) are 39.7 and 39.0 days, 52.8 and 52.0 days, 60.4 and 59.0 days, 49.8 and 50.0 days, and 60.0 and 61.0 days, respectively. Log-rank testing showed that Groups B, C, D, and E all had a significantly longer survival time than Group A (all P = 0.000). Groups C and E could prolong the survival time longer than Group B (all P = 0.000) and Group D (C versus D, P = 0.003; E versus D, P = 0.005). There was no significant difference in survival prolongation between Groups B and D (P = 0.462) or between Groups C and E (P = 0.500).